Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study-Reference-Cited by-同舟云学术

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study

Published:2014-01 Issue:1 Volume:2 Page:e51-e57
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Mondal Dinesh,Alvar Jorge,Hasnain Md Golam,Hossain Md Shakhawat,Ghosh Debashis,Huda M Mamun,Nabi Shah Golam,Sundar Shyam,Matlashewski Greg,Arana Byron

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. Leishmaniasis worldwide and global estimates of its incidence;Alvar;PLoS One,2012

2. Regional strategic framework for elimination of kala-azar from south-east Asia region (2005–2015),2005

3. Developments in the treatment of visceral leishmaniasis;den Boer;Expert Opin Emerg Drugs,2009

4. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh;Rahman;Am J Trop Med Hyg,2011

5. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance;Rijal;Clin Infect Dis,2013

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A model of vector-targeted interventions for visceral leishmaniasis;The Lancet Infectious Diseases;2024-08

2. Synthetic biology for combating leishmaniasis;Frontiers in Microbiology;2024-02-01

3. Progress in the application of nanoparticles for the treatment of fungal infections: A review;Mycology;2023-12-08

4. Leishmania Species (Leishmaniasis);Principles and Practice of Pediatric Infectious Diseases;2023

5. Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis;Frontiers in Tropical Diseases;2022-05-12